Yokoyama Y, Kaji H, Kondoh H, Takeuchi E, Yamasaki Y, Inui Y
Department of Obstetrics and Gynecology, Kochi Red Cross Hospital, Kochi City, Japan.
Gynecol Obstet Invest. 2001;52(3):210-4. doi: 10.1159/000052976.
The survival rate of patients with advanced-stage mucinous cystadenocarcinoma of the ovary is dismal and no best treatment is known. We report a case of complete response of a stage IV mucinous cystadenocarcinoma of the ovary to systemic chemotherapy employing paclitaxel and carboplatin.
A 51-year-old nullipara diagnosed with International Federation of Gynecology and Obstetrics stage IV mucinous cystadenocarcinoma of the ovary underwent cytoreductive surgery followed by systemic chemotherapy employing paclitaxel and carboplatin every 4 weeks for 3 courses. The patient tolerated chemotherapy well, demonstrated a remarkable response showing no evidence of malignancy at a second-look laparotomy. As a consolidation chemotherapy after negative second-look laparotomy, she underwent another three courses of chemotherapy of the same regimen, and is showing no evidence of disease.
Paclitaxel and carboplatin may be effective in treating mucinous cystadenocarcinoma of the ovary.
晚期卵巢黏液性囊腺癌患者的生存率很低，目前尚无最佳治疗方案。我们报告1例IV期卵巢黏液性囊腺癌患者经紫杉醇联合卡铂全身化疗后完全缓解的病例。
一名51岁未生育女性被诊断为国际妇产科联盟IV期卵巢黏液性囊腺癌，接受了肿瘤细胞减灭术，随后每4周接受1次紫杉醇联合卡铂全身化疗，共3个疗程。患者对化疗耐受性良好，二次剖腹探查时显示出显著疗效，未发现恶性肿瘤迹象。作为二次剖腹探查阴性后的巩固化疗，她又接受了3个疗程相同方案的化疗，目前未发现疾病迹象。
紫杉醇和卡铂可能对治疗卵巢黏液性囊腺癌有效。
